These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 23274936

  • 1. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults.
    Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A.
    J Acquir Immune Defic Syndr; 2013 Apr 15; 62(5):525-33. PubMed ID: 23274936
    [Abstract] [Full Text] [Related]

  • 2. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
    Calza L, Danese I, Colangeli V, Vandi G, Manfredi R, Girometti N, Borderi M, Appolloni L, Puggioli C, Viale P.
    AIDS Res Hum Retroviruses; 2014 Dec 15; 30(12):1162-9. PubMed ID: 25369244
    [Abstract] [Full Text] [Related]

  • 3. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
    Monteiro P, Perez I, Pich J, Gatell JM, Martínez E.
    J Antimicrob Chemother; 2013 Feb 15; 68(2):404-8. PubMed ID: 23109185
    [Abstract] [Full Text] [Related]

  • 4. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
    Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P, C.I.S.A.I. Group, Italy.
    Int J Antimicrob Agents; 2015 Mar 15; 45(3):289-94. PubMed ID: 25476452
    [Abstract] [Full Text] [Related]

  • 5. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
    Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H, Protocol 004 Part II Study Team.
    J Acquir Immune Defic Syndr; 2009 Nov 01; 52(3):350-6. PubMed ID: 19648823
    [Abstract] [Full Text] [Related]

  • 6. Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report.
    Cirioni O, Weimer LE, Fragola V, Giacometti A, Gabrielli E, Marchionni E, Massella M, Barchiesi F.
    West Indian Med J; 2013 Nov 01; 62(4):377-9. PubMed ID: 24756601
    [Abstract] [Full Text] [Related]

  • 7. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P, SWITCHMRK 1 and 2 investigators.
    Lancet; 2010 Jan 30; 375(9712):396-407. PubMed ID: 20074791
    [Abstract] [Full Text] [Related]

  • 8. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, STARTMRK Investigators.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):77-85. PubMed ID: 23412015
    [Abstract] [Full Text] [Related]

  • 9. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar 01; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 10. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M, ISS-NIA Group.
    Ann Pharmacother; 2010 May 01; 44(5):838-43. PubMed ID: 20371753
    [Abstract] [Full Text] [Related]

  • 11. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar 01; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 12. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 study group.
    Clin Infect Dis; 2009 Oct 15; 49(8):1259-67. PubMed ID: 19757993
    [Abstract] [Full Text] [Related]

  • 13. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
    Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, Gérard L, Lascoux-Combe C, Molina JM, Taburet AM.
    Antimicrob Agents Chemother; 2010 Feb 15; 54(2):937-9. PubMed ID: 19995925
    [Abstract] [Full Text] [Related]

  • 14. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
    Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S.
    Int J STD AIDS; 2010 Nov 15; 21(11):783-5. PubMed ID: 21187364
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.
    Scand J Infect Dis; 2014 Jan 15; 46(1):34-45. PubMed ID: 24161018
    [Abstract] [Full Text] [Related]

  • 16. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O.
    Invest New Drugs; 2017 Apr 15; 35(2):247-249. PubMed ID: 27838867
    [Abstract] [Full Text] [Related]

  • 17. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E, Tommasi C, Abbate I, Bonora S, Tempestilli M, Bellagamba R, Viscione M, Rozera G, Gallo AL, Ivanovic J, Amendola A, Pucillo L, Di Perri G, Capobianchi MR, Narciso P.
    Antivir Ther; 2011 Apr 15; 16(6):797-803. PubMed ID: 21900711
    [Abstract] [Full Text] [Related]

  • 18. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM, ANRS 12 180 Reflate TB study group.
    Lancet Infect Dis; 2014 Jun 15; 14(6):459-67. PubMed ID: 24726095
    [Abstract] [Full Text] [Related]

  • 19. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group.
    AIDS; 2010 Jul 17; 24(11):1697-707. PubMed ID: 20467288
    [Abstract] [Full Text] [Related]

  • 20. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A, Weimer LE, Manfredi R, Fragola V, Ferrari C.
    West Indian Med J; 2012 Dec 17; 61(9):932-6. PubMed ID: 24020238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.